| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Annette Gower, Mario Tiber. The Intersection of Central Dopamine System and Stroke: Potential Avenues Aiming at Enhancement of Motor Recovery. Frontiers in synaptic neuroscience. vol 10. 2020-10-01. PMID:30034335. |
parkinson's disease and schizophrenia are two major human neuropsychiatric disorders typically associated with dysfunctional dopamine activity levels, which can be alleviated through the druggability of the dopaminergic systems. |
2020-10-01 |
2023-08-13 |
human |
| Annette Gower, Mario Tiber. The Intersection of Central Dopamine System and Stroke: Potential Avenues Aiming at Enhancement of Motor Recovery. Frontiers in synaptic neuroscience. vol 10. 2020-10-01. PMID:30034335. |
here, we discuss the state of knowledge regarding the modulation of dopaminergic systems following stroke, and the use of dopamine boosting therapies in animal stroke models to improve stroke recovery. |
2020-10-01 |
2023-08-13 |
human |
| Braulio Muñoz, Gonzalo E Yevenes, Benjamin Förstera, David M Lovinger, Luis G Aguay. Presence of Inhibitory Glycinergic Transmission in Medium Spiny Neurons in the Nucleus Accumbens. Frontiers in molecular neuroscience. vol 11. 2020-10-01. PMID:30050406. |
it is believed that the rewarding actions of drugs are mediated by dysregulation of the mesolimbic dopaminergic system leading to increased levels of dopamine in the nucleus accumbens (nac). |
2020-10-01 |
2023-08-13 |
Not clear |
| Jonathan Timpka, Tove Henriksen, Per Odi. Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How? Movement disorders clinical practice. vol 3. issue 3. 2020-10-01. PMID:30363573. |
in pd, the degeneration of dopaminergic neurons leads to a reduced capacity to buffer dopamine, which could increase the vulnerability to a pulsatile administration of drugs. |
2020-10-01 |
2023-08-13 |
Not clear |
| John Liang, Mark Groves, Vicki L Shanke. Clozapine Treatment for Impulse Control Disorders in Parkinson's Disease Patients: A Case Series. Movement disorders clinical practice. vol 2. issue 3. 2020-10-01. PMID:30363600. |
all 4 took dopaminergic medications at the time that icds developed; all received dopamine agonist therapy. |
2020-10-01 |
2023-08-13 |
Not clear |
| Susanna Jakobson Mo, Jan Linder, Lars Forsgren, Katrine Riklun. Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism. Movement disorders clinical practice. vol 2. issue 1. 2020-10-01. PMID:30363855. |
dopamine transporter (dat) imaging may be supportive in the initial clinical diagnostic workup in patients with suspected parkinsonian diseases, given that the method has the potential to detect dopaminergic degeneration. |
2020-10-01 |
2023-08-13 |
Not clear |
| Sun Ryu, Hyongjun Jeon, Sungtae Koo, Seungtae Ki. Korean Red Ginseng Enhances Neurogenesis in the Subventricular Zone of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mice. Frontiers in aging neuroscience. vol 10. 2020-10-01. PMID:30459594. |
after the last pole test, dopaminergic neuronal survival in the striatum and the substantia nigra (sn), cell proliferation in the svz and mrna expression of neurotrophic factors and dopamine receptors in the striatum were evaluated. |
2020-10-01 |
2023-08-13 |
mouse |
| Sun Ryu, Hyongjun Jeon, Sungtae Koo, Seungtae Ki. Korean Red Ginseng Enhances Neurogenesis in the Subventricular Zone of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mice. Frontiers in aging neuroscience. vol 10. 2020-10-01. PMID:30459594. |
krg administration suppressed dopaminergic neuronal death induced by mptp in the striatum as well as the sn, augmented the number of brdu- and brdu/doublecortin (dcx)-positive cells in the svz and enhanced the expression of proliferation cell nuclear antigen, brain derived neurotrophic factor (bdnf), glial cell derived neurotrophic factor (gdnf), cerebral dopamine neurotrophic factor (cdnf), ciliary neurotrophic factor (cntf), dopamine receptor d3 (drd3) and d5 mrnas. |
2020-10-01 |
2023-08-13 |
mouse |
| Michelino Puopol. The hypothalamic-spinal dopaminergic system: a target for pain modulation. Neural regeneration research. vol 14. issue 6. 2020-10-01. PMID:30761995. |
hypothalamic a11 dopaminergic neurons project to all levels of the spinal cord and provide the main source of spinal dopamine. |
2020-10-01 |
2023-08-13 |
human |
| Elisa Caggiu, Giannina Arru, Sepideh Hosseini, Magdalena Niegowska, GianPietro Sechi, Ignazio Roberto Zarbo, Leonardo A Sech. Inflammation, Infectious Triggers, and Parkinson's Disease. Frontiers in neurology. vol 10. 2020-10-01. PMID:30837941. |
parkinson's disease is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons of the substantia nigra pars compacta with a reduction of dopamine concentration in the striatum. |
2020-10-01 |
2023-08-13 |
Not clear |
| Robert S Eisinger, Adolfo Ramirez-Zamora, Samuel Carbunaru, Brandon Ptak, Zhongxing Peng-Chen, Michael S Okun, Aysegul Gundu. Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease. Frontiers in neurology. vol 10. 2020-10-01. PMID:30863353. |
although it is now well-recognized that dopaminergic treatments and especially dopamine agonists underpin many icds, medications alone are not the sole cause. |
2020-10-01 |
2023-08-13 |
Not clear |
| Robert S Eisinger, Adolfo Ramirez-Zamora, Samuel Carbunaru, Brandon Ptak, Zhongxing Peng-Chen, Michael S Okun, Aysegul Gundu. Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease. Frontiers in neurology. vol 10. 2020-10-01. PMID:30863353. |
beyond dopamine, other icd associations have been described but remain difficult to explain, including deep brain stimulation surgery, especially in the setting of a reduction in dopaminergic medication use. |
2020-10-01 |
2023-08-13 |
Not clear |
| Krista Farrell, Roger A Barke. Stem cells and regenerative therapies for Parkinson's disease. Degenerative neurological and neuromuscular disease. vol 2. 2020-10-01. PMID:30890881. |
currently the mainstay of parkinson's disease (pd) therapy is the pharmacological replacement of the loss of the dopaminergic nigrostriatal pathway using drugs such as dopamine agonists and levodopa. |
2020-10-01 |
2023-08-13 |
Not clear |
| Krista Farrell, Roger A Barke. Stem cells and regenerative therapies for Parkinson's disease. Degenerative neurological and neuromuscular disease. vol 2. 2020-10-01. PMID:30890881. |
indeed all these studies have provided evidence that following the transplantation of fetal vm tissue, dopaminergic cells can survive long term, produce dopamine, and bring about clinical improvements in younger patients over many years. |
2020-10-01 |
2023-08-13 |
Not clear |
| Hui Dong, Juan Wang, Yan-Fei Yang, Yan Shen, Wei-Min Qu, Zhi-Li Huan. Dorsal Striatum Dopamine Levels Fluctuate Across the Sleep-Wake Cycle and Respond to Salient Stimuli in Mice. Frontiers in neuroscience. vol 13. 2020-10-01. PMID:30949023. |
here, we employed an intensity-based genetically encoded dopamine indicator, dlight1.1, to track striatal dopamine levels across the spontaneous sleep-wake cycle and the dopaminergic response to external stimuli. |
2020-10-01 |
2023-08-13 |
mouse |
| Nicholas G Norwitz, Michele T Hu, Kieran Clark. The Mechanisms by Which the Ketone Body D-β-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease. Frontiers in nutrition. vol 6. 2020-10-01. PMID:31139630. |
although dopamine replacement therapy temporarily helps patients manage their motor symptoms, this current standard of care fails to address the underlying network of pathologies that contribute to the persistent death of dopaminergic neurons. |
2020-10-01 |
2023-08-13 |
Not clear |
| Erika Coletto, John S Dolan, Sara Pritchard, Alex Gant, Atsuko Hikima, Michael J Jackson, Christopher D Benham, K Ray Chaudhuri, Sarah Rose, Peter Jenner, Mahmoud M Iravan. Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson's disease. NPJ Parkinson's disease. vol 5. 2020-10-01. PMID:31231674. |
the absence of the relaxation and the inefficacy of l-name in the mptp tissues suggests that central dopaminergic loss dopamine may eventually lead to the impairment of no signal coupling that affects bowel function, and this may be the result of a complex dysregulation at the level of the neuroeffector junction. |
2020-10-01 |
2023-08-13 |
marmoset |
| Ashley L Green, Aseel Eid, Le Zhan, Helmut Zarbl, Grace L Guo, Jason R Richardso. Epigenetic Regulation of the Ontogenic Expression of the Dopamine Transporter. Frontiers in genetics. vol 10. 2020-10-01. PMID:31749842. |
the dopamine transporter (dat) is a plasma membrane transport protein responsible for regulating the duration and intensity of dopaminergic signaling. |
2020-10-01 |
2023-08-13 |
rat |
| Miguel A Pieron. Investigation of apomorphine during sleep in Parkinson's: Improvement in UPDRS Scores. Neurology international. vol 11. issue 4. 2020-10-01. PMID:31871600. |
this study proposes that dopaminergic deficit may be responsible for the circadian dysregulation that occur with neurodegeneration and therefore a restitution of rem sleep and an improvement in parkinson disease's symptoms can be achieved with the controlled use of dopamine agonists during the night. |
2020-10-01 |
2023-08-13 |
Not clear |
| Shashank Vasudevan, Janko Kajtez, Ada-Ioana Bunea, Ana Gonzalez-Ramos, Tania Ramos-Moreno, Arto Heiskanen, Merab Kokaia, Niels B Larsen, Alberto Martínez-Serrano, Stephan S Keller, Jenny Emnéu. Leaky Optoelectrical Fiber for Optogenetic Stimulation and Electrochemical Detection of Dopamine Exocytosis from Human Dopaminergic Neurons. Advanced science (Weinheim, Baden-Wurttemberg, Germany). vol 6. issue 24. 2020-10-01. PMID:31871869. |
leaky optoelectrical fiber for optogenetic stimulation and electrochemical detection of dopamine exocytosis from human dopaminergic neurons. |
2020-10-01 |
2023-08-13 |
human |